166 related articles for article (PubMed ID: 20848473)
21. The incidence and management of infusion reactions to infliximab: a large center experience.
Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
[TBL] [Abstract][Full Text] [Related]
24. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
Stephens MC; Shepanski MA; Mamula P; Markowitz JE; Brown KA; Baldassano RN
Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944
[TBL] [Abstract][Full Text] [Related]
25. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
26. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
27. Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers.
Eshuis EJ; Peters CP; van Bodegraven AA; Bartelsman JF; Bemelman W; Fockens P; D'Haens GR; Stokkers PC; Ponsioen CY
Inflamm Bowel Dis; 2013 Jul; 19(8):1622-30. PubMed ID: 23552767
[TBL] [Abstract][Full Text] [Related]
28. Durability of infliximab in Crohn's disease: a single-center experience.
Gonzaga JE; Ananthakrishnan AN; Issa M; Beaulieu DB; Skaros S; Zadvornova Y; Johnson K; Otterson MF; Binion DG
Inflamm Bowel Dis; 2009 Dec; 15(12):1837-43. PubMed ID: 19462426
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years.
Lönnkvist MH; Befrits R; Lundberg JO; Lundahl J; Fagerberg UL; Hjortswang H; van Hage M; Hellström PM
Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1168-76. PubMed ID: 19757522
[TBL] [Abstract][Full Text] [Related]
30. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.
Katz L; Gisbert JP; Manoogian B; Lin K; Steenholdt C; Mantzaris GJ; Atreja A; Ron Y; Swaminath A; Shah S; Hart A; Lakatos PL; Ellul P; Israeli E; Svendsen MN; van der Woude CJ; Katsanos KH; Yun L; Tsianos EV; Nathan T; Abreu M; Dotan I; Lashner B; Brynskov J; Terdiman JP; Higgins PD; Chaparro M; Ben-Horin S
Inflamm Bowel Dis; 2012 Nov; 18(11):2026-33. PubMed ID: 22294554
[TBL] [Abstract][Full Text] [Related]
31. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ
Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
[TBL] [Abstract][Full Text] [Related]
32. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Price S; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2012 Sep; 107(9):1409-22. PubMed ID: 22890223
[TBL] [Abstract][Full Text] [Related]
33. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
[TBL] [Abstract][Full Text] [Related]
35. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands.
de Ridder L; Escher JC; Bouquet J; Schweizer JJ; Rings EH; Tolboom JJ; Houwen RH; Norbruis OF; Derkx BH; Taminiau JA
J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):46-52. PubMed ID: 15187780
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
[TBL] [Abstract][Full Text] [Related]
37. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
38. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.
Teshima CW; Thompson A; Dhanoa L; Dieleman LA; Fedorak RN
Can J Gastroenterol; 2009 May; 23(5):348-52. PubMed ID: 19440565
[TBL] [Abstract][Full Text] [Related]
39. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
40. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
